|
1
|
Peach CJ, Mignone VW, Arruda MA, Alcobia
DC, Hill SJ, Kilpatrick LE and Woolard J: Molecular pharmacology of
VEGF-A isoforms: Binding and Signalling at VEGFR2. Int J Mol Sci.
19(pii): E12642018. View Article : Google Scholar
|
|
2
|
Bowler E and Oltean S: Alternative
splicing in angiogenesis. Int J Mol Sci. 20:20672019. View Article : Google Scholar :
|
|
3
|
Higa GM and Abraham J: Biological
mechanisms of bevacizumab-associated adverse events. Expert Rev
Anticancer Ther. 9:999–1007. 2009. View Article : Google Scholar
|
|
4
|
Lacal PM and Graziani G: Therapeutic
implication of vascular endothelial growth factor receptor-1
(VEGFR-1) targeting in cancer cells and tumour microenvironment by
competitive and non-competitive inhibitors. Pharmacol Res.
136:97–107. 2018. View Article : Google Scholar
|
|
5
|
Lacal PM, Ruffini F, Pagani E and D'Atri
S: An autocrine loop directed by the vascular endothelial growth
factor promotes invasiveness of human melanoma cells. Int J Oncol.
27:1625–1632. 2005.
|
|
6
|
Levati L, Ruffini F, Muzi A, Umezawa K,
Graziani G, D'Atri S and Lacal PM: Placenta growth factor induces
melanoma resistance to temozolomide through a mechanism that
involves the activation of the transcription factor NF-κB. Int J
Oncol. 38:241–247. 2011.
|
|
7
|
Li C, Liu B, Dai Z and Tao Y: Knockdown of
VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration,
angiogenesis and growth of clear cell renal cell carcinoma (CRCC).
Cancer Biol Ther. 12:872–880. 2011. View Article : Google Scholar :
|
|
8
|
Atzori MG, Tentori L, Ruffini F, Ceci C,
Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, et
al: The anti-vascular endothelial growth factor receptor-1
monoclonal antibody D16F7 inhibits invasiveness of human
glioblastoma and glioblastoma stem cells. J Exp Clin Cancer Res.
36:1062017. View Article : Google Scholar :
|
|
9
|
Cao Y: Positive and negative modulation of
angiogenesis by VEGFR1 ligands. Sci Signal. 24(2): re12009.
|
|
10
|
Abou-Fayçal C, Hatat AS, Gazzeri S and
Eymin B: Splice variants of the RTK family: Their Role in tumour
progression and response to targeted therapy. Int J Mol Sci.
18(pii): 3832017. View Article : Google Scholar :
|
|
11
|
Stevens M and Oltean S: Modulation of
receptor tyrosine kinase activity through alternative splicing of
ligands and receptors in the VEGF-A/VEGFR Axis. Cells. 8(pii):
E2882019. View Article : Google Scholar
|
|
12
|
Sia D, Alsinet C, Newell P and Villanueva
A: VEGF signaling in cancer treatment. Curr Pharm Des.
20:2834–2842. 2014. View Article : Google Scholar
|
|
13
|
Atzori MG, Tentori L, Ruffini F, Ceci C,
Bonanno E, Scimeca M, Lacal PM and Graziani G: The anti-vascular
endothelial growth factor receptor-1 monoclonal antibody D16F7
inhibits glioma growth and angiogenesis in vivo. J Pharmacol Exp
Ther. 364:77–86. 2018. View Article : Google Scholar
|
|
14
|
Graziani G, Ruffini F, Tentori L, Scimeca
M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S and
Lacal PM: Antitumour activity of a novel anti-vascular endothelial
growth factor receptor-1 monoclonal antibody that does not
interfere with ligand binding. Oncotarget. 7:72868–72885. 2016.
View Article : Google Scholar :
|
|
15
|
Weller M: Next generation neuro-oncology.
Eur J Cancer. 96:1–5. 2018. View Article : Google Scholar
|
|
16
|
Lu VM, Jue TR, McDonald KL and Rovin RA:
The survival effect of repeat surgery at glioblastoma recurrence
and its trend: A systematic review and meta-analysis. World
Neurosurg. 115:453–459.e3. 2018. View Article : Google Scholar
|
|
17
|
Diaz RJ, Ali S, Qadir MG, De La Fuente MI,
Ivan ME and Komotar RJ: The role of bevacizumab in the treatment of
glioblastoma. J Neurooncol. 133:455–467. 2017. View Article : Google Scholar
|
|
18
|
Hundsberger T, Reardon DA and Wen PY:
Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert
Rev Anticancer Ther. 17:507–515. 2017. View Article : Google Scholar
|
|
19
|
Tipping M, Eickhoff J and Ian Robins H:
Clinical outcomes in recurrent glioblastoma with bevacizumab
therapy: An analysis of the literature. J Clin Neurosci.
44:101–106. 2017. View Article : Google Scholar :
|
|
20
|
Itatani Y, Kawada K, Yamamoto T and Sakai
Y: Resistance to anti-angiogenic therapy in cancer-alterations to
anti-VEGF pathway. Int J Mol Sci. 19(pii): E12322018. View Article : Google Scholar
|
|
21
|
Dello Russo C, Lisi L, Tentori L, Navarra
P, Graziani G and Combs CK: Exploiting microglial functions for the
treatment of glioblastoma. Curr Cancer Drug Targets. 17:267–281.
2017. View Article : Google Scholar
|
|
22
|
Hiratsuka S, Nakamura K, Iwai S, Murakami
M, Itoh T, Kijima H, Shipley JM, Senior RM and Shibuya M: MMP9
induction by vascular endothelial growth factor receptor-1 is
involved in lung-specific metastasis. Cancer Cell. 2:289–300. 2002.
View Article : Google Scholar
|
|
23
|
Rolny C, Mazzone M, Tugues S, Laoui D,
Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et
al: HRG inhibits tumour growth and metastasis by inducing
macrophage polarization and vessel normalization through
downregulation of PlGF. Cancer Cell. 19:31–44. 2011. View Article : Google Scholar
|
|
24
|
Zhou X and Qi Y: Larynx carcinoma
regulates tumour-associated macrophages through PLGF signaling. Sci
Rep. 5:100712015. View Article : Google Scholar :
|
|
25
|
Li N, Qin J, Lan L, Zhang H, Liu F, Wu Z,
Ni H and Wang Y: PTEN inhibits macrophage polarization from M1 to
M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism. Cancer
Biol Ther. 16:297–306. 2015. View Article : Google Scholar :
|
|
26
|
Incio J, Tam J, Rahbari NN, Suboj P,
McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, et
al: PlGF/VEGFR-1 signaling promotes macrophage polarization and
accelerated tumour progression in obesity. Clin Cancer Res.
22:2993–3004. 2016. View Article : Google Scholar :
|
|
27
|
Lisi L, Stigliano E, Lauriola L, Navarra P
and Dello Russo C: Proinflammatory-activated glioma cells induce a
switch in microglial polarization and activation status, from a
predominant M2b phenotype to a mixture of M1 and M2a/B polarized
cells. ASN Neuro. 6:171–183. 2014. View Article : Google Scholar
|
|
28
|
Lisi L, Laudati E, Navarra P and Dello
Russo C: The mTOR kinase inhibitors polarize glioma-activated
microglia to express a M1 phenotype. J Neuroinflammation.
11:1252014. View Article : Google Scholar :
|
|
29
|
Laudati E, Currò D, Navarra P and Lisi L:
Blockade of CCR5 receptor prevents M2 microglia phenotype in a
microglia-glioma paradigm. Neurochem Int. 108:100–108. 2017.
View Article : Google Scholar
|
|
30
|
Lisi L, Ciotti GM, Braun D, Kalinin S,
Currò D, Dello Russo C, Coli A, Mangiola A, Anile C, Feinstein DL
and Navarra P: Expression of iNOS, CD163 and ARG-1 taken as M1 and
M2 markers of microglial polarization in human glioblastoma and the
surrounding normal parenchyma. Neurosci Lett. 645:106–112. 2017.
View Article : Google Scholar
|
|
31
|
Lisi L, Ciotti GMP, Chiavari M,
Pizzoferrato M, Mangiola A, Kalinin S, Feinstein DL and Navarra P:
Phospho-mTOR expression in human glioblastoma microglia-macrophage
cells. Neurochem Int. 129:1044852019. View Article : Google Scholar
|
|
32
|
Chiavari M, Ciotti GMP, Navarra P and Lisi
L: Pro-inflammatory activation of a new immortalized human
microglia cell line. Brain Sci. 9(pii): E1112019. View Article : Google Scholar
|
|
33
|
Ruffini F, Failla CM, Orecchia A, Bani MR,
Dorio AS, Fortes C, Zambruno G, Graziani G, Giavazzi R, D'Atri S
and Lacal PM: Expression of the soluble vascular endothelial growth
factor receptor-1 in cutaneous melanoma: Role in tumour
progression. Br J Dermatol. 164:1061–1070. 2011. View Article : Google Scholar
|
|
34
|
Friedman HS, Prados MD, Wen PY, Mikkelsen
T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen
R, et al: Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009.
View Article : Google Scholar
|
|
35
|
Kreisl TN, Kim L, Moore K, Duic P, Royce
C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al:
Phase II trial of single-agent bevacizumab followed by bevacizumab
plus irinotecan at tumour progression in recurrent glioblastoma. J
Clin Oncol. 27:740–745. 2009. View Article : Google Scholar
|
|
36
|
Wick W, Gorlia T, Bendszus M, Taphoorn M,
Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al:
Lomustine and bevacizumab in progressive glioblastoma. N Engl J
Med. 377:1954–1963. 2017. View Article : Google Scholar
|
|
37
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar
|
|
38
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar :
|
|
39
|
Piao Y, Liang J, Holmes L, Zurita AJ,
Henry V, Heymach JV and de Groot JF: Glioblastoma resistance to
anti-VEGF therapy is associated with myeloid cell infiltration,
stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol.
14:1379–1392. 2012. View Article : Google Scholar :
|
|
40
|
Gabrusiewicz K, Liu D, Cortes-Santiago N,
Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM,
Idoate MA, et al: Anti-vascular endothelial growth factor
therapy-induced glioma invasion is associated with accumulation of
Tie2-expressing monocytes. Oncotarget. 5:2208–2220. 2014.
View Article : Google Scholar :
|
|
41
|
Lu-Emerson C, Snuderl M, Kirkpatrick ND,
Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda
DG, et al: Increase in tumour-associated macrophages after
antiangiogenic therapy is associated with poor survival among
patients with recurrent glioblastoma. Neuro Oncol. 15:1079–1087.
2013. View Article : Google Scholar :
|
|
42
|
Castro BA, Flanigan P, Jahangiri A,
Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR,
Mascharak S, et al: Macrophage migration inhibitory factor
downregulation: A novel mechanism of resistance to anti-angiogenic
therapy. Oncogene. 36:3749–3759. 2017. View Article : Google Scholar :
|
|
43
|
Kitamura T, Qian BZ and Pollard JW: Immune
cell promotion of metastasis. Nat Rev Immunol. 15:73–86. 2015.
View Article : Google Scholar :
|
|
44
|
Pollard JW: Trophic macrophages in
development and disease. Nat Rev Immunol. 9:259–270. 2009.
View Article : Google Scholar :
|
|
45
|
Melton DW, McManus LM, Gelfond JA and
Shireman PK: Temporal phenotypic features distinguish polarized
macrophages in vitro. Autoimmunity. 48:161–176. 2015. View Article : Google Scholar :
|
|
46
|
Jetten N, Verbruggen S, Gijbels MJ, Post
MJ, De Winther MP and Donners MM: Anti-inflammatory M2, but not
pro-inflammatory M1 macrophages promote angiogenesis in vivo.
Angiogenesis. 17:109–118. 2014. View Article : Google Scholar
|
|
47
|
Lamszus K, Ulbricht U, Matschke J,
Brockmann MA, Fillbrandt R and Westphal M: Levels of soluble
vascular endothelial growth factor (VEGF) receptor 1 in astrocytic
tumours and its relation to malignancy, vascularity, and VEGF-A.
Clin Cancer Res. 9:1399–1405. 2003.
|
